About the Journal

Journal of Nephropharmacology; where nephrologist meets pharmacologist

Journal of Nephropharmacology is a peer-reviewed scientific journal publishes every six months in January and July of each year.

This international journal publishes manuscripts in the fields of physiology, kidney transplantation, nephrology, and hypertension with regard to the treatment of these diseases in both basic and clinical research. This journal aims to reach all relevant national and international medical institutions and persons in electronic version.

It has pursued this aim by publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypotheses, case reports, epidemiology and prevention, news and views, and photo-clinics in all features of  nephrology  and renal transplantation.

 In this journal, particular emphasis is given to research, on both experimental and clinical nephrology, aimed at the protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between nephrologists and pharmacologists.

 In addition, this journal welcomes basic biomedical and pharmaceutical scientific research applied to clinical nephrology and also pharmacology. In this journal papers related to the all aspects of diabetes will be peer-reviewed. The futuristic conceptual hypothesis that integrates various fields of acute kidney injury and renal tubular cell protection is encouraged to be submitted.

 The journal allows free access (Open Access) to its contents and permits authors to self-archive the final accepted version of the articles.

Aims and Scope

Nephropharmacology is the intersection between nephrology and clinical Pharmacology. Journal of Nephropharmacology considers the following topics; mechanisms of drug elimination by the kidneys, drug therapy and renal transplantation, drug therapy of co-morbidity in renal disease patients, and renal toxicity of drugs. In addition, the specific aspects of pharmacokinetics and drug dose adjustment in patients with disturbed renal function has significant importance in this journal. This journal affiliated to the Society of Diabetic Nephropathy Prevention, thus all manuscripts related to diabetes, particularly diabetic nephropathy will be peer-reviewed. This journal also considers papers on hypertension.

Journal’s Characteristics

Full Journal Name:  Journal of Nephropharmacology

ISO Abbreviation: J. Nephropharmacol.

Journal’s Email: jnephropharmacol@gmail.com, admin@jnephropharmacology.com

Publisher:  Society of Diabetic Nephropathy Prevention

Publisher’s link: http://sdiabeticnephropathy.com

Publisher Office:  No.19, Stage 2, Hakim Build, Ferdowsi St. Isfahan, Iran, Postal code# 8143995119

Publisher’s Email: sdn@sdiabeticnephropathy.com

 Language: English

Frequency:  Two issues/year

Category: Medical Sciences (Drug therapy in renal disease, Nephrology, Renal transplantation, Pharmacotherapy of kidney disease, electrolyte imbalance, and COVID-19)

Open Access: Open Access

Publication Fee: Yes

Complaint email: No specific policy– we handle complaints on a case-by-case basis

Email: jnephropharmacol@gmail.com

Cell phone: +98 9121439584

Editorial Policy

Open Access

The Journal of Nephropharmacology follows the Budapest Open Access Initiative (BOAI) funding model through the following link; https://www.budapestopenaccessinitiative.org/ (2019).

All content to the Journal of Nephropharmacology is freely available to readers/ authors and all institutions without a limitation period. Individuals can search, copy, print, read and download and also distribute full texts of the papers.

 In this journal, the accepted articles by peer review will be published under a Creative Commons Attribution License (CC-BY) https://creativecommons.org/licenses/by/4.0/ (2019). In the Journal of Nephropharmacology, no charge is needed for submitting the manuscripts.

Author fees

Regarding the publication fee, please see the following link; https://www.jnephropharmacology.com/PublicationFee

Permissions

It is the duty of the authors to get permission from copyright containers for copying photos, figures or tables that will not be published. The authors should submit the certification of permission along with the submission.

Disclaimer

Facts and opinions in papers published in the Journal of Nephropharmacology connected to the Society of Diabetic Nephropathy Prevention are uniquely the personal statements of respective authors. Authors are responsible for all contents in their article(s) including accuracy of the facts, statements, and citing the resources

Advertising Policy

The Journal of Nephropharmacology does not publish advertisements. This journal also has not any direct marketing actions, counting the requesting of papers.

The journal’s policy on preprint articles

Authors are not allowed to submit preprint papers.

Publication Ethics and Malpractice Statement

Publication and authorship

1. All submitted manuscripts to the Journal of Nephropharmacology are subject to a strict peer-review process by at least two international reviewers and one local reviewer that are experts in the area of endocrinology/nephrology.
2. The factors that are taken into account in the review are relevance, soundness, significance, originality, readability, and language.
3. The possible decisions include acceptance, acceptance with revisions, or rejection.
4. If authors are encouraged to revise and resubmit a submission, there is no guarantee that the revised submission will be accepted.
5. Rejected manuscripts will not be re-reviewed.
6. The manuscript acceptance is constrained by such legal requirements as shall then be in force regarding libel, copyright infringement, and plagiarism.
7. No research can be included in more than one publication.

Authors' responsibilities

1. Authors must certify that their manuscripts are their original work.
2. Authors must certify that the manuscript has not previously been published elsewhere.
3. Authors must certify that the manuscript is not currently being considered for publication elsewhere.
4. Authors must participate in the peer review process.
5. Authors are obliged to provide retractions or corrections of mistakes.
6. All Authors mentioned in the paper must have significantly contributed to the research.
7. Authors must state that all data in the paper are real and authentic.
8. Authors must notify the editors of any conflicts of interest.
9. Authors must identify all sources used in the creation of their manuscripts.
10. Authors must report any errors they discover in their published papers to the editors.

Please complete the authors’ agreement form provided on the journal website and send it through email to the journal.

Reviewers' responsibilities

1. Reviewers should keep all information regarding papers confidential and treat them as privileged information.
2. Reviews should be conducted objectively, with no personal criticism of the author
3. Reviewers should express their views clearly with supporting arguments
4. Reviewers should identify relevant published work that has not been cited by the authors.
5. Reviewers should also call to the editor-in-chief's attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.
6. Reviewers should not review manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

For more information, please look at the checklist for review provided on the journal website.

Editors' responsibilities

1. Editors have complete responsibility and authority to reject/accept an article.
2. Editors are responsible for the contents and overall quality of the publication.
3. Editors should always consider the needs of the authors and the readers when attempting to improve the publication.
4. Editors should guarantee the quality of the papers and the integrity of the academic record.
5. Editors should publish errata pages or make corrections when needed.
6. Editors should have a clear picture of a research's funding sources.
7. Editors should base their decisions solely on the paper's importance, originality, clarity, and relevance to the publication's scope.
8. Editors should not reverse their decisions nor overturn the ones of previous editors without serious reason.
9. Editors should preserve the anonymity of reviewers.
10. Editors should ensure that all research material they publish conforms to internationally accepted ethical guidelines.
11. Editors should only accept a paper when reasonably certain.
12. Editors should act if they suspect misconduct, whether a paper is published or unpublished, and make all reasonable attempts to persist in obtaining a resolution to the problem.
13. Editors should not reject papers based on suspicions; they should have proof of misconduct.
14. Editors should not allow any conflicts of interest between staff, authors, reviewers, and board members.

Plagiarism

Journal of Nephropharmacology is committed on publishing only original materials (materials that neither have been published elsewhere nor are under review elsewhere). Journal of Nephropharmacology is powered by the iThenticate^® software, a plagiarism detector software that detects the originality of content submitted before publication. If plagiarism is recognized, we act based on flowcharts and workflows regulated by the COPE.

Plagiarism could be the following items

• Direct copying the text from other articles
• Copying concepts, photos, or data from other published sources
• Copying the text from the own previously published materials

Plagiarism Policies

If plagiarism is recognized, the manuscript will be rejected. Additionally, if plagiarism is detected after the publication of the paper, they will retract according to the COPE guidelines.

Duplicate Submission

Papers, which have been published elsewhere, or to be under review elsewhere, will incur duplicate submission/publication sanctions. If authors have used their own previously published study, or study that is currently under review, as the basis for a submitted manuscript, they are required to cite the previous paper and indicate how their submitted manuscript offers novel contributions beyond those of the previous work.

Citation Manipulation

Submitted papers that are found to include citations whose primary purpose is to increase the number of citations to a given author’s article, or to articles published in a particular journal, will incur citation manipulation sanctions.

Data Fabrication and Falsification

Submitted papers that are found to have either fabricated or falsified experimental results, including the manipulation of images, will incur data fabrication and falsification sanctions.

Improper Author Contribution or Attribution

All listed authors must have made a significant scientific contribution to the study in the paper and approved all its claims. It is important to list everyone who made a significant scientific contribution, including students and laboratory technicians.

Redundant Publications

Redundant publications involve the inappropriate division of study outcomes into several articles.

Process for Identification of and Dealing with Allegations of Research Misconduct

  Society of Diabetic Nephropathy Prevention (http://sdiabeticnephropathy.com)  as the publisher and the Editor-in-Chief of the Journal of Nephropharmacology will take practical steps, which comprise technological and personal knowledge available to identify and block the publication of papers where research misconduct has arisen, containing citation manipulation, plagiarism, and data falsification/fabrication among others. The Journal of Nephropharmacology respects the COPE's guidelines (http://publicationethics.org/resources/guidelines) in dealing with allegations.

Editorial Freedom

The Journal of Nephropharmacology follows to the World Association of Medical Editors (WAME) Policy on “The Relationship between Journal Editors-in-Chief and Owners”. Accordingly, the Editor-in-Chief has editorial independence and therefore has full authority over the journal’s editorial content counting how and when information is published. Editorial decisions are based solely on the validity of the papers and their importance to readers, not on the policies or commercial interests of the owner. Neither the Publisher nor other organizations interfere in the evaluation, selection, or editing of individual articles, either directly or by creating an environment in which editorial decisions are influenced.

CrossMark Policy

CrossMark is a multi-publisher initiative to offer a standard system for readers to find the current version of a piece of content. Through utilizing the CrossMark logo, this journal is committing to keeping the content it and notifying the readers of changes when it occurs.

All papers have the CrossMark logo in PDF. Clicking on the CrossMark logo at the top of each article in a PDF file will indicate the status of a document and may also give additional data about the document.

For more information on CrossMark, please check the CrossMark website by the following link:

https://www.crossref.org/services/crossmark/

 Privacy Statement

The characteristics of the authors containing names and email addresses, which are registered on the journal’s website, will be conducted only for the aims of the journal and will not be directed for any other reason.

Author Agreement Form

The agreement form of the article should be completed and signed by the authors, along with the submission. This form should be sent by the corresponding author through the following email too. Email; jnephropharmacol@gmail.com

The  Journal of Nephropharmacology is an Open Access Journal distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits anyone to copy, redistribute, remix, transmit and adapt the work provided the original work and source is appropriately cited. Upon submitting an article, authors are requested to specify their agreement to abide by an open-access Creative Commons license (CC BY 4.0). Under the terms of this license, authors retain ownership of the copyright of their articles. The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive. Abstracts and PDF format of all articles published by this journal are freely available to everyone instantly upon publication.

Retraction

In keeping with COPE's Retraction Guidelines, a retraction will be considered by our editors if: 

• It has clear evidence indicating the results are unreliable, either because of major errors (eg, miscalculation or experimental error, data fabrication, image manipulation, …)
• It has plagiarism.
• The findings have previously been published elsewhere without proper citation to previous sources, permission to reproduce, or justification (ie, cases of redundant publication)
• There is a copyright infringement or other legal issues
• It reports unethical research
• It has been published solely on the basis of a compromised or manipulated peer review process
• The author(s) failed to declare a major conflict of interest

Authors or editors of the journal may retract a paper. However, the final decision is made by the editors for retracting the material. If none of the authors will approve publishing a retraction, the editor/s may request such a retraction from the investigating institution, or the editor may ask for a retraction on behalf of the journal. In each condition, the editor should inform the author(s) or institution affiliated with the author(s) for publishing a retraction.

• Note: After publishing a retraction, HTML version of the document will be removed from the site. Additionally, The PDF file of the article is retained unchanged; only a watermark showing the “retracted” label is placed on each page of the PDF. Finally, a link is made to the original article.

Publisher & Owner

   Society of Diabetic Nephropathy Prevention (http://sdiabeticnephropathy.com)